; Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent; Whereas prostate cancer is almost always diagnosed with a needle biopsy where the prostate is mapped and tissue cores are removed from at least a dozen sites; Whereas even with state-of-the-art laboratory techniques and specimen tracking, peer-reviewed literature reports that as many as 2.5 percent of prostate biopsy patients are affected by biopsy tissue switching or contamination leading to misdiagnosis; Whereas misdiagnosis can result in inappropriate overtreatment or undertreatment of men; Whereas only 30 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized; Whereas there are no noticeable symptoms of prostate cancer in the early stages, making appropriate screening critical; Whereas ongoing research promises further improvements in prostate cancer prevention, early detection, and treatment; and Whereas educating people in the United States, including health care providers, about prostate cancer and early detection strategies is crucial to saving the lives of men and preserving and protecting families: Now, therefore, be it